Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421267 | 0.94 | TMEM97 (0.46) | TMEM97SIGMAR1PTGDR2DHFRMEN1 | |
| SCHEMBL3340495 | 0.92 | TMEM97 (0.49) | TMEM97SIGMAR1PTGDR2DHFRKDR | |
| SCHEMBL3337973 | 0.89 | TMEM97 (0.46) | TMEM97SIGMAR1PTGDR2DHFRMEN1 | |
| SCHEMBL21315070 | 0.82 | TMEM97 (0.45) | TMEM97SIGMAR1PTGDR2DHFRMEN1 | |
| SCHEMBL3338693 | 0.82 | TMEM97 (0.48) | TMEM97SIGMAR1PTGDR2DHFRKDR | |
| SCHEMBL21315051 | 0.82 | TMEM97 (0.43) | TMEM97SIGMAR1PTGDR2DHFRMEN1 | |
| SCHEMBL19616489 | 0.81 | TMEM97 (0.46) | TMEM97SIGMAR1PTGDR2MEN1KMT2A | |
| SCHEMBL30835148 | 0.80 | TMEM97 (0.41) | TMEM97SIGMAR1PTGDR2DHFRMEN1 | |
| SCHEMBL19616526 | 0.80 | TMEM97 (0.43) | TMEM97SIGMAR1PTGDR2DHFRMEN1 | |
| SCHEMBL22440456 | 0.80 | LMNA (0.40) | PTGDR2ALDH1A1GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240300980-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116194456-A | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022247760-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | 上海科州药物研发有限公司 | 2022-12-01 | — | — | WO | disclosed |
| EP-3880208-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20200308170-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-10-01 | — | — | US | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | TMEM97 988/4885SIGMAR1 1764/4885PTGDR2 1727/4885 |
| US-20240300980-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | KRAS, NRAS, HRAS | TMEM97 3639/4885SIGMAR1 4254/4885PTGDR2 1379/4885 |
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TMEM97 3851/4885SIGMAR1 4812/4885PTGDR2 2675/4885 |
| US-20200308170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TMEM97 3851/4885SIGMAR1 4812/4885PTGDR2 2675/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TMEM97 3851/4885SIGMAR1 4812/4885PTGDR2 2675/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | TMEM97 985/4885SIGMAR1 1357/4885PTGDR2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.